For the year ending 2025-12-31, HRGN had -$1,134K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Regenerative Biotech | 0 |
| Consumer Health Products | 704 |
| Product revenue | 704 |
| Regenerative Biotech | 0 |
| Consumer Health Products | 646 |
| Cost of sales | 646 |
| Regenerative Biotech | 2,653 |
| Consumer Health Products | 0 |
| Research and development | 2,653 |
| Sales and marketing | 67 |
| General and administrative | 4,253 |
| Total operating expenses | 7,619 |
| Other segment items | -46 |
| Net loss | -6,869 |
| Share-based compensation expense | 2,010 |
| Depreciation | 5 |
| Amortization of operating lease right-of-use assets | 98 |
| Accounts receivable | -215 |
| Inventory | -64 |
| Prepaid research and development | -72 |
| Prepaid expenses and other current assets | -149 |
| Deferred financing costs | 0 |
| Long-term prepaid contracts | -257 |
| Accounts payable | 2 |
| Operating lease liability | -95 |
| Accrued and other current liabilities | 311 |
| Deferred revenue | 252 |
| Insurance premium financing payable | -299 |
| Net cash used in operating activities | -3,828 |
| Proceeds from convertible debt related party | 0 |
| Proceeds from issuance of common stock | 2,700 |
| Proceeds from exercise of warrants | 0 |
| Payments on convertible debt related party | 0 |
| Net cash provided by financing activities | 2,700 |
| Effect of exchange rate changes on cash | -6 |
| Net (decrease) increase in cash and cash equivalents | -1,134 |
| Cash and cash equivalents at the beginning of the year | 2,486 |
| Cash and cash equivalents at the end of the year | 1,352 |
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. (HRGN)